World leader in tires, Michelin is also a key player in innovation in the medical world.
In a certain discretion, the Bibendum manufactures and sells components for implantable medical devices, as well as technologies for the biopharmaceutical market.
Today, the tire giant announces that it will market airbags under its brand for intensive care patients tested in the midst of the Covid crisis.
To discover
Find all the results of the legislative elections
Taxes 2022: all about your tax return
Read alsoMichelin: turnover up 19% in the first quarter, objectives confirmed
Indeed, at the end of 2021, Michelin acquired AirCaptif, a small French company specializing in ultralight inflatable structures (tents, shelters, sofas, etc.) which a priori have nothing to do with medicine.
However, this activity has found several variations in the medical world.
First, this subsidiary manufactures clean rooms for emergencies, which can be deployed in less than an hour.
Seven cushions are distributed under the patient's body to relieve him.
Michelin
Reduce bedsores and facilitate ventilation
Above all, at the height of the Covid pandemic, when thousands of patients were plunged into a coma, AirCaptif developed with the University Hospital of Amiens, inflatable cushions for patients in respiratory distress placed in the prone position.
Seven cushions are thus distributed under the body of the patient to relieve him.
This solution is intended to reduce bedsores and facilitate ventilation.
It has been tested in nine French hospitals in recent months.
Today, Michelin announces that it markets under its own brand this kit of seven cushions called Michelin AirProne.
The French group, which today generates 95% of its turnover in tires, intends to increase this share to 75%, or even 70% by 2030. It is diversifying into several areas to ensure relays of growth:
